Glaucoma Therapeutics Market
Glaucoma is a disease that damages the optic nerve and its progression could result in vision loss and blindness. Treatment of glaucoma starts with topical eye drops belonging to the class of prostaglandins, beta blockers, alpha agonist, combination medication, carbonic anhydrase inhibitor, and cholinergic. Administration of these eye drops reduces the production of the fluid inside eyes, thereby decreasing intraocular pressure. Topical eye drops is an alternative for surgery or to delay surgical procedure.
The global glaucoma therapeutics market was valued at US$ 5,932.6 Mn in 2017 is anticipated to reach US$ 7,659.8 Mn by 2026, expanding at a CAGR of 2.9% from 2018 to 2026. Increase in prevalence and incidence of diabetic disorders, rise in geriatric population, improved health care as well as health care infrastructure, introduction of combination therapies, and surge in the number of awareness programs are likely to drive the global glaucoma therapeutics market during the forecast period. Lack of awareness about eye disorders, non-compliance with treatment, side effects of glaucoma drugs, and growth of the generic drugs market are anticipated to restrain the global market in the near future. However, emerging economies such as India, China, Brazil, Russia, Mexico, and South Africa offer immense opportunities in the glaucoma therapeutics market. This is attributed to large number of underserved patients, rise in proportion of urban population, and insurance policies. Moreover, governments of the nations mentioned above have taken initiatives to educate the people about glaucoma and its management.
The global glaucoma therapeutics market has been segmented based on drug class, end-user, and region. In terms of drug class, the global market has been classified into prostaglandins, beta blockers, alpha agonist, combination medication, and carbonic anhydrase inhibitors and cholinergic. Prostaglandins analogs are the molecules that bind to the prostaglandin receptor increasing the outflow of the fluid from the eyes and reducing intraocular pressure. Beta blockers are also commonly used topical drugs, which act by reducing the production of fluid inside the eyes. Combination medications are eye drops used in patients who require more than one medication. Cholinergic agents aid in the treatment of glaucoma by contracting the ciliary muscles, tightening the trabecular meshwork, and increasing the outflow of fluid. Carbonic anhydrase inhibitor and alpha agonist are used to increase the outflow of fluid from the eyes, thereby reducing intraocular pressure. Prostaglandins, beta blockers, and combination medication are the most widely used topical agents. The combination medication segment is projected to account for the largest share of the market during the forecast period, followed by beta blockers and prostaglandins. However, rise in prevalence of glaucoma globally has fueled the growth of the combination medication segment. The segment is expected to expand at a high CAGR during the forecast period. Rise in awareness about early detection of glaucoma and provision of affordable treatment options are expected to boost the growth of the combination medication segment during the forecast period.
In terms of end-user, the hospitals segment captured major share of the global glaucoma therapeutics market in 2017. The segment is likely to sustain its leadership position during the forecast period. A large population prefers visiting hospitals first rather than specialty clinics for treatment, as the cost of therapy at hospitals is lower. Ambulatory surgical center is the less preferred option for the treatment of glaucoma.
Geographically, the global glaucoma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe accounted for a combined market share of 50.2% in 2017. North America is projected to continue to dominate the market during the forecast period due to increase in the geriatric population, rise in awareness among the population about glaucoma, availability of reimbursements, and well-established health care infrastructure. The market in Asia Pacific is expected to expand at a high CAGR during the forecast period. However, the market in Latin America and Middle East & Africa is anticipated to witness sluggish growth during the forecast period. Increase in focus by federal governments on enhancing health care facilities and rise in awareness among the population are the factors contributing to the growth of the market in these regions.
Major players operating in the global glaucoma therapeutics market are Allergan, Inc., Merck & Co., Pfizer, Inc., Novartis AG., Santen Pharmaceuticals, Valeant Pharmaceuticals, and Aerie Pharmaceuticals. Players in the generics market are Fera Pharmaceuticals, Teva Pharmaceuticals, and Aristo Pharmaceuticals, among others. The market is characterized by large number of acquisitions, which has led to market consolidation and increasing dominance of the top players.
The global glaucoma therapeutics Market has been segmented as follows:
|
Drug Class |
|
|
End-user |
|
|
Geography |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Glaucoma Therapeutics Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Glaucoma Therapeutics Market Analysis and Forecasts, 2016–2026
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Value Chain Analysis
5.2. Disease Prevalence & Incidence Rate, by Region
5.3. Healthcare Industry Overview
5.4. Pipeline Analysis
6. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2016–2026
6.3.1. Prostaglandins
6.3.2. Beta Blockers
6.3.3. Alpha Agonists
6.3.4. Carbonic Anhydrase Inhibitors
6.3.5. Combination Medications
6.3.6. Cholinergics
6.4. Market Attractiveness, by Drug Class
7. Global Glaucoma Therapeutics Market Analysis and Forecasts, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2016–2026
7.3.1. Hospitals
7.3.2. Ophthalmic Clinics
7.3.3. Ambulatory Surgical Centers
7.4. Market Attractiveness, by End-user
8. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Glaucoma Therapeutics Market Analysis and Forecast
9.1. Introduction
9.2. Market Value Forecast, by Drug Class, 2016–2026
9.2.1. Prostaglandins
9.2.2. Beta Blockers
9.2.3. Alpha Agonists
9.2.4. Carbonic Anhydrase Inhibitors
9.2.5. Combination Medications
9.2.6. Cholinergics
9.3. Market Value Forecast, by End-user, 2016–2026
9.3.1. Hospitals
9.3.2. Ophthalmic Clinics
9.3.3. Ambulatory Surgical Centers
9.4. Market Value Forecast, by Country, 2016–2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By End-user
9.5.3. By Country
10. Europe Glaucoma Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast, by Drug Class, 2016–2026
10.2.1. Prostaglandins
10.2.2. Beta Blockers
10.2.3. Alpha Agonists
10.2.4. Carbonic Anhydrase Inhibitors
10.2.5. Combination Medications
10.2.6. Cholinergics
10.3. Market Value Forecast, by End-user, 2016–2026
10.3.1. Hospitals
10.3.2. Ophthalmic Clinics
10.3.3. Ambulatory Surgical Centers
10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Glaucoma Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast, by Drug Class, 2016–2026
11.2.1. Prostaglandins
11.2.2. Beta Blockers
11.2.3. Alpha Agonists
11.2.4. Carbonic Anhydrase Inhibitors
11.2.5. Combination Medications
11.2.6. Cholinergics
11.3. Market Value Forecast, by End-user, 2016–2026
11.3.1. Hospitals
11.3.2. Ophthalmic Clinics
11.3.3. Ambulatory Surgical Centers
11.4. Market Value Forecast, by Country/Sub-region, 2016–2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Glaucoma Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast, by Drug Class, 2016–2026
12.2.1. Prostaglandins
12.2.2. Beta Blockers
12.2.3. Alpha Agonists
12.2.4. Carbonic Anhydrase Inhibitors
12.2.5. Combination Medications
12.2.6. Cholinergics
12.3. Market Value Forecast, by End-user, 2016–2026
12.3.1. Hospitals
12.3.2. Ophthalmic Clinics
12.3.3. Ambulatory Surgical Centers
12.4. Market Value Forecast, by Country/Sub-region, 2016–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Glaucoma Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast, by Drug Class, 2016–2026
13.2.1. Prostaglandins
13.2.2. Beta Blockers
13.2.3. Alpha Agonists
13.2.4. Carbonic Anhydrase Inhibitors
13.2.5. Combination Medications
13.2.6. Cholinergics
13.3. Market Value Forecast, by End-user, 2016–2026
13.3.1. Hospitals
13.3.2. Ophthalmic Clinics
13.3.3. Ambulatory Surgical Centers
13.4. Market Value Forecast, by Country/Sub-region, 2016–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix
14.2. Market Share Analysis, by Company (2016)
14.3. Company Profiles
14.3.1. Allergan plc
14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2 Financial Overview
14.3.1.3 Product Portfolio
14.3.1.4 SWOT Analysis
14.3.1.5 Strategic Overview
14.3.2. Merck & Co., Inc.
14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2 Financial Overview
14.3.2.3 Product Portfolio
14.3.2.4 SWOT Analysis
14.3.2.5 Strategic Overview
14.3.3. Novartis AG
14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2 Financial Overview
14.3.3.3 Product Portfolio
14.3.3.4 SWOT Analysis
14.3.3.5 Strategic Overview
14.3.4. Pfizer Inc.
14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2 Financial Overview
14.3.4.3 Product Portfolio
14.3.4.4 SWOT Analysis
14.3.4.5 Strategic Overview
14.3.5. Santen Pharmaceuticals Co. Ltd.
14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2 Financial Overview
14.3.5.3 Product Portfolio
14.3.5.4 SWOT Analysis
14.3.5.5 Strategic Overview
14.3.6. Valeant Pharmaceuticals International, Inc.
14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2 Financial Overview
14.3.6.3 Product Portfolio
14.3.6.4 SWOT Analysis
14.3.6.5 Strategic Overview
14.3.7. Aerie Pharmaceuticals Inc.
14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.7.4 Strategic Overview
List of Tables
Table 01: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 03: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 04: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 05: North America Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 06: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 07: U.S. Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 08: U.S. Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 09: Canada Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 10: Canada Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 11: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 12: Europe Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 13: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: U.K. Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 15: U.K. Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 16: Germany Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 17: Germany Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 18: France Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 19: France Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 20: Spain Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 21: Spain Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 22: Italy Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 23: Italy Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 24: Rest of Europe Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 25: Rest of Europe Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 26: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 27: Asia Pacific Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 28: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 29: Japan Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 30: Japan Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 31: China Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 32: China Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 33: India Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 34: India Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 35: Australia & New Zealand Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 36: Australia & New Zealand Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 37: Rest of APAC Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 38: Rest of APAC Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 39: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 40: Latin America Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 41: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 42: Brazil Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 43: Brazil Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 44: Mexico Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 45: Mexico Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 46: Rest of LATAM Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 47: Rest of LATAM Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 48: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 49: Middle East & Africa Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 50: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 51: GCC Countries Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 52: GCC Countries Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 53: South Africa Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 54: South Africa Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 55: Rest of MEA Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 56: Rest of MEA Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
List of Figures
Figure 01: Global Glaucoma Therapeutics Market Snapshot
Figure 02: Global Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2026
Figure 03: Market Value Share, by Drug Class (2017)
Figure 04: Market Value Share, by End-user (2017)
Figure 05: Market Value Share, by Region (2017)
Figure 06: Global Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 07: Global Prostaglandins Market Revenue (US$ Mn), 2016–2026
Figure 08: Global Beta Blockers Market Revenue (US$ Mn), 2016–2026
Figure 09: Global Alpha Agonist Market, Revenue (US$ Mn), 2016–2026
Figure 10: Global Carbonic Anhydrase Inhibitor (CAI) Market, Revenue (US$ Mn), 2016–2026
Figure 11: Global Combination Medications Market, Revenue (US$ Mn), 2016–2026
Figure 12: Global Cholinergic Market, Revenue (US$ Mn), 2016–2026
Figure 13: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 14: Global Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 15: Global Hospitals Market Revenue (US$ Mn), 2016–2026
Figure 16: Global Ophthalmic Clinics Market Revenue (US$ Mn), 2016–2026
Figure 17: Global Ambulatory Surgical Centers Market Revenue (US$ Mn), 2016–2026
Figure 18: Global Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 19: Global Glaucoma Therapeutics Market Value Share Analysis, by Region, 2017 and 2026
Figure 20: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Region, 2018–2026
Figure 21: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 22: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country
Figure 23: North America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 24: North America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 25: North America Glaucoma Therapeutics Market, by Country, 2017 and 2026
Figure 26: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 27: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 28: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 29: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-Region
Figure 30: Europe Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 31: Europe Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 32: Europe Glaucoma Therapeutics Market, by Country/Sub-region
Figure 33: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 34: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 35: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 36: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-Region
Figure 37: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 38: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 39: Asia Pacific Glaucoma Therapeutics Market, by Country/Sub-region
Figure 40: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 41: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 42: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 43: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region
Figure 44: Latin America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 45: Latin America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 46: North America Glaucoma Therapeutics Market, by Country/Sub-region
Figure 47: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 48: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 49: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 50: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region
Figure 51: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 52: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 53: Middle East & Africa Glaucoma Therapeutics Market, by Country/Sub-region
Figure 54: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 55: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 56: Global Glaucoma Therapeutics Market Share Analysis, by Company (2017)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes